Summary:
Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible dose titration, efficacy and safety study of SPD489 in combination with an antidepressant in the treatment of adults with Major Depressive Disorder with inadequate response to prospective treatment with an antidepressant.
Qualified Participants Must:
• Be depressed
•
Not have a diagnosis of ADD/ADHD
•
Have a BMI between 18 and 40
•
Have blood pressure below 140/90
•
Be willing and able to comply with the study protocol
Qualified Participants May Receive:
compensation for time and travel